ArticleInfectious diseases & immunity2026
Early initiation of antiviral treatment for two infants with acute HBV infection: Beneficial or unfavorable?
Article in Infectious diseases & immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mother-to-child transmission is the major route of hepatitis B virus (HBV) infection in children, and antiviral therapy is generally deferred in infancy due to presumed immune tolerance. Here, we report the clinical course and treatment response of two infants younger than 6 months with HBV infection who initiated antiviral therapy due to elevated serum transaminase levels indicative of an immune-active status. Notably, Case #01 achieved a functional cure after 25 months of antiviral treatment. Case #02 did not achieve a functional cure but attained HBV DNA clearance and HBeAg seroconversion at 12 and 5 months of therapy, respectively. At the last follow-up visit (month 67), the HBsAg level of Case #02 was 10.70 IU/mL. These findings suggest that early antiviral intervention, initiated before 6 months of age, may be beneficial for infants with HBV infection who are in an immune-active status. A potential treatment window may exist even during early infancy; however, treatment strategies should be individualized and guided by careful clinical assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.